Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.

17 May 2012

CINJ prefers more personalized approach to prescribing cancer treatment

With recent advancements in technology and biomedical informatics, a more personalized approach to prescribing cancer treatment and developing these therapies is preferred over "one-size-fits-all" methods.

16 May 2012

Vermillion first quarter total revenue increases to $312,000

Vermillion, Inc., a leading molecular diagnostics company, reported financial and operational results for the first quarter ended March 31, 2012.

From Quest Diagnostics 16 May 2012

Poor women and African Americans with ovarian cancer less likely to receive care

Poor women and African Americans with ovarian cancer are less likely to receive the highest standards of care, leading to worse outcomes than among white and affluent patients, according to a study of 50,000 women presented by UC Irvine's Dr. Robert Bristow at the Society of Gynecologic Oncology's annual meeting March 27.

9 May 2012

Basser Research Center to focus on treatment and prevention of inherited cancers

A $25 million gift to the University of Pennsylvania from alumni Mindy and Jon Gray will establish a center focused on the treatment and prevention of cancers associated with hereditary BRCA mutations.

9 May 2012

Rexahn submits Phase II protocol for Archexin clinical study for ovarian cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).

8 May 2012

Screening younger men at risk of prostate cancer can reduce metastatic cancer and deaths

Screening younger men and men at risk of prostate cancer can be beneficial in reducing metastatic cancer and deaths and should not be abandoned, states an article published in CMAJ (Canadian Medical Association Journal).

8 May 2012

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012.

21 Apr 2012

Inform Genomics completes first phase in oral mucositis risk prediction study

Inform Genomics, Inc., a private company focused on developing novel platforms of personalized medicine products for cancer supportive care and inflammatory diseases, today announced the completion of the first phase of product development to predict a patient's risk of developing oral mucositis after receiving high dose chemotherapy prior to hematopoietic stem cell transplant.

19 Apr 2012

MD Anderson to conduct 15th annual Sprint for Life event on May 5

Ovarian cancer survivors, their friends and families, local businesses, corporate teams and employees of The University of Texas MD Anderson Cancer Center will join forces May 5 at the 15th annual Sprint for Life 5K Run/Walk and Sprint for Sprouts Kids' Run. The approximately 3,000 participants will come together for a common cause: to build awareness of ovarian cancer and raise funds for research.

17 Apr 2012

Merck, Endocyte enter vintafolide development and commercialization agreement

Merck, known as MSD outside the United States and Canada, and Endocyte Inc., today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145).

16 Apr 2012

Tool predicts response to platinum-based chemotherapy in ovarian cancer

A DNA repair pathway-focused score has the potential to help determine if first-line platinum based chemotherapy can benefit advanced-stage ovarian cancer patients, according to a study published April 13 in the Journal of the National Cancer Institute.

16 Apr 2012

Ovarian cancer screening may not be needed on routine basis for all women says panel

In its latest review since 2004 of the benefits and harms of ovarian cancer screening, the United States Preventive Services Task Force found no new evidence to support routine screening.

12 Apr 2012

Soon a vaccine that targets 90% of all cancers

Results from the safety trial - on patients with blood cancer - found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition.

10 Apr 2012

Bimodal genes can define molecular subtypes of ovarian cancer

Scientists from Duke University Medical Center have determined that genes acting as molecular "on/off" switches can define clinically relevant molecular subtypes of ovarian cancer, providing ideal potential targets for use in clinical prognostic and diagnostic testing.

9 Apr 2012

Gold nanostars can deliver drug directly to cancer cell nucleus

Nanotechnology offers powerful new possibilities for targeted cancer therapies, but the design challenges are many. Northwestern University scientists now are the first to develop a simple but specialized nanoparticle that can deliver a drug directly to a cancer cell's nucleus -- an important feature for effective treatment.

6 Apr 2012

Uterine cancer up by 43% in UK over last two decades

Figures show that the number of diagnoses remained static for many years, but has increased by 43% since the 1990s. As the number of womb cancer cases have increased over the last decade, so have the number of womb cancer deaths. However, survival has also improved during that period, with 77% of women who are diagnosed with womb cancer now surviving for five years or more.

5 Apr 2012

Height and ovarian cancer link and diagnosis woes

A review of studies has revealed that taller women have a slightly higher risk of ovarian cancer. Obesity is also a risk factor among women who have never taken HRT, say international researchers. Previous studies have suggested a link, but there has been conflicting evidence.

4 Apr 2012

Study: Functional link between two major causes of treatment failure in breast cancer

Research from The Cancer Institute of New Jersey (CINJ) shows a functional link between two major causes of treatment failure in breast cancer, showing the protein behind one of these causes plays a role in increasing the drug resistance properties of the other.

4 Apr 2012

Genomic fortune-telling fails to provide informative guidance to most people

With sharp declines in the cost of whole genome sequencing, the day of accurately deciphering disease risk based on an individual's genome may seem at hand. But a study involving data of thousands of identical twins by Johns Hopkins investigators finds that genomic fortune-telling fails to provide informative guidance to most people about their risk for most common diseases, and warns against complacency born of negative genome test results.

3 Apr 2012